The federal government's public comment window on how vaccine recommendations are labeled closes Sunday, September 20. The docket remains open to anyone until then.
The request for information, published in the Federal Register under Docket No. HHS-OS-2026-0332, runs five pages and asks 18 questions. It was issued by the Department of Health and Human Services in support of the Task Force on Safer Childhood Vaccines and in furtherance of an August 10 executive order on childhood vaccine recommendations.
For families, the stakes are less abstract than the subject line suggests. One of the 18 questions deals directly with insurance. Federal recommendations determine what private plans must cover without cost sharing under the Affordable Care Act and what is available through the Vaccines for Children program. Changing the labels can change the paperwork attached to a shot at the pharmacy counter.
Three Labels That Decide Whether a Shot Is the Default
Federal vaccine recommendations currently fall into three categories. A routine, or universal, recommendation means the default is to vaccinate everyone in an age group. A risk-based recommendation applies to people with a specific medical or exposure-related risk factor. A shared clinical decision-making recommendation, which the department also calls individual-based decision-making, has no default at all, and the decision is made one patient at a time.
The notice asks whether those three are clear enough, whether new ones should be added, and whether shared clinical decision-making should be renamed something like conditional recommendation. It also asks what considerations should govern which label a vaccine receives, including the appropriate approach when randomized trial evidence is limited or absent.
The department is explicit, in its announcement of the request and in the notice itself, that this is not a rule and changes no existing recommendation, coverage requirement, or program obligation. The notice also says the department will not respond to commenters individually.
Coverage Confusion Is Already Documented, and It Reaches the Pharmacy Counter
The notice lays out survey evidence that the middle category is poorly understood. In a national survey of family physicians and internists published in 2021, 90 to 95 percent said these recommendations take more time than routine ones, fewer than half knew the vaccines were covered by insurance, and many reported that their electronic health records displayed the recommendations incorrectly or not at all.
That gap has a household consequence. A shared clinical decision-making recommendation, once adopted, triggers the same insurance coverage requirements as a routine one. A parent told a vaccine is optional may reasonably assume it is also not covered, and skip it on cost grounds that do not exist.
Uptake differences are measurable. In the 2025 National Immunization Survey-Teen, 90.8 percent of 17-year-olds had received the routinely recommended meningococcal ACWY vaccine. For meningococcal B, which has sat in the permissive category since 2015 and under shared clinical decision-making since 2019, the figure was 36.3 percent, and only 12.5 percent had received at least two doses. The two vaccines cover different strains, so this is not a controlled comparison, but the contrast is striking.
A Stanford Physician's Read on the Gaps in the Notice
Writing in a CIDRAP opinion piece, Dr. Jake Scott, a clinical associate professor of infectious diseases at Stanford University School of Medicine, argued that the category's practical effect is larger than its name implies. "In a busy clinic, no default is a default," he wrote. CIDRAP notes that opinion pieces reflect the author's views rather than its official position.
His central criticism is about scope. None of the 18 questions asks whether the vaccines moved off the routine schedule in January belong where they were placed. He also notes that the notice cites the reconstituted advisory committee's 2025 votes as examples of the individual-based category without mentioning that a federal district court stayed those votes, and the January memo, in March, in a case that remains active.
He raised a second gap. Among the new labels the notice floats is "recommended, but not during infancy," and the notice does not say which vaccine would go there. Scott points to the hepatitis B birth dose as the one recommendation that exists specifically for the first days of life.
The department's own framing is different. It argues that clear, evidence-based and transparent recommendations help people make informed decisions, and it asks how the framework should reflect the strength of the evidence, individual circumstances and public trust.
Filing a Comment Before the Sunday Cutoff
Comments go to regulations.gov under docket HHS-OS-2026-0332, or by mail to the address listed in the notice. Everything submitted, including a name, is posted publicly, so personal details are best left out.
Commenters do not have to answer all 18 questions, and the notice says so directly. Pediatric practices have the most to say about the questions on clarity and time burden. Labor and delivery nurses are closest to the proposed infancy-timing category. Pharmacists are named in the notice's list of intended respondents.
The deadline is not the end of the process. The August executive order that prompted the notice gave the Task Force on Safer Childhood Vaccines 90 days to deliver plans on the childhood schedule, which places that milestone in early November. Comments filed by Sunday enter the record that informs that work.
Nothing about this notice changes what a clinician should do next week. Existing recommendations, coverage requirements and program eligibility all remain as they are, and no vaccine has moved between categories because of this docket.
Anyone unsure whether a family member is up to date should check records with a provider or pharmacist rather than waiting on a federal decision. Anyone told a vaccine falls under shared clinical decision-making can also ask directly whether their plan covers it, since the answer is usually yes.
Key Questions Answered
What is the deadline? Comments must be received by Sunday, September 20, 2026, under Docket No. HHS-OS-2026-0332.
What is actually being decided? Nothing yet. This is a request for information that gathers public input. It is not a rule and changes no current recommendation or coverage rule.
What are the three categories? Routine or universal, risk-based, and shared clinical decision-making, which the department also calls individual-based decision-making.
Could this affect insurance coverage? Potentially. Category assignment drives no-cost-sharing coverage under the Affordable Care Act and Vaccines for Children eligibility, and one question addresses the consequences of category assignment.
Who is HHS asking to comment? Parents and patients, clinicians, nurses and pharmacists, state and local health officials, health plans, researchers and manufacturers, among others.
Do commenters have to answer everything? No. The notice invites partial responses.
What happens after Sunday? Comments feed into plans the Task Force on Safer Childhood Vaccines is due to deliver in early November.
